MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/tid.13213

Медицинская библиотека · Transplant infectious disease : an official journal of the Transplantation Society · 2019

BK Polyomavirus-associated nephropathy managed by screening policy in a real-life setting.

Raupp Fernanda Vianna Vacilotto, Meinerz Gisele, da Silva Cynthia Keitel, Bianco Patrícia Campos d'Almeida, Goldani João Carlos, Pegas Karla Lais, Stolfo Josiane Borges, Garcia Valter Duro, Keitel Elizete

СтатьяПеревод в очереди

Аннотация

BACKGROUND

BK polyomavirus-associated nephropathy (PyVAN) is an important complication after kidney transplantation. Prevalence ranges from 1% to 10%, and graft loss occurs in approximately 50% of the cases. There is no effective treatment, so early viral detection with immunosuppression tapering is the current strategy to prevent PyVAN.

AIMS: To verify the frequency of PyVAN in a single center and evaluate the response to immunosuppressive adjustments through graft survival analysis.

METHODS

Retrospective evaluation of a cohort of kidney transplant recipients with biopsy-proven PyVAN, compared with no-PyVAN patients regarding clinical aspects, immunosuppression, and graft survival over at least 2 years.

RESULTS

There were 1404 kidney transplants analyzed in the study period, 58 with biopsy-proven PyVAN. Cumulative incidence was 4.1%. Median time from transplantation to PyVAN diagnosis was 6 (1-41) months. PyVAN was associated with recipient male gender (P = .041) and deceased donation (P = .005). Graft survival was inferior for PyVAN compared to no-PyVAN patients, 81.8% vs 75.2%, P = .019. Thirteen (22.4%) PyVAN patients lost their grafts, nine (15.5%) losses attributed to BKPyV infection. Three patients with BKPyV-associated graft losses were submitted to a successful second kidney transplant, with no evidence of viral replication during follow-up.

CONCLUSION

PyVAN still is an important cause of kidney graft failure. Even though implementing active vigilance and immunosuppressive adjustment, this real-life single-center study demonstrated inferior graft survival in PyVAN patients compared to non-PyVAN.

Для цитирования: Raupp Fernanda Vianna Vacilotto, Meinerz Gisele, da Silva Cynthia Keitel, Bianco Patrícia Campos d'Almeida, Goldani João Carlos, Pegas Karla Lais, Stolfo Josiane Borges, Garcia Valter Duro, Keitel Elizete. BK Polyomavirus-associated nephropathy managed by screening policy in a real-life setting.. Transplant infectious disease : an official journal of the Transplantation Society. 2019. DOI: 10.1111/tid.13213.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.